Vivozon Pharmaceutical announced on the 28th the launch of ‘Tru-PN,’ a tissue restoration biomaterial injected into the knee joint cavity to reduce physical friction in the joint area and control pain.
Tru-PN is a polymer DNA complex primarily composed of Polynucleotide. When injected into the joint cavity of patients with knee osteoarthritis, the high-viscosity and elastic polymer material acts as a buffer at the cartilage defect site, reducing physical friction in the joint, controlling pain, and aiding movement.
Additionally, for patients with mild to moderate (K-L grade I, II, III) knee osteoarthritis, up to five injections within six months are covered by health insurance, reducing the economic burden on patients.
Tru-PN is safe as it is produced using patented technology from raw materials extracted from a single species of domestically sourced salmonid fish, subjected to strict traceability and quality control. Furthermore, clinical trials on Korean subjects have demonstrated its efficacy and safety, showing reduced knee pain both during weight-bearing and rest, as well as significant improvements in physical function and stiffness index after the procedure.
Meanwhile, Vivozon Pharmaceutical applied for product approval from the Ministry of Food and Drug Safety last year for the non-opioid analgesic Onapraju (generic name: Opranzerin). Onapraju’s indication is moderate to severe acute pain, including postoperative pain.
A Vivozon Pharmaceutical official stated, “In addition to Onapraju, Vivozon Pharmaceutical holds various central nervous system pipelines and plans to actively expand its business through continuous research and development.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
